Home/Pipeline/Bempikibart (ADX-914)

Bempikibart (ADX-914)

Alopecia Areata

Phase 2aActive; Fast Track Designation; in SIGNAL-AA trialNCT06037829

Key Facts

Indication

Alopecia Areata

Phase

Phase 2a

Status

Active; Fast Track Designation; in SIGNAL-AA trial

Company

Q32 Bio

About Q32 Bio

Q32 Bio's mission is to transform patient lives by rebalancing the immune system through targeted modulation of innate and adaptive immune pathways. The company has achieved Fast Track designation for its lead candidate, bempikibart, in alopecia areata and is advancing a Phase 2a trial. Its strategy leverages a dual-pronged approach: advancing its adaptive immune modulator in high-need autoimmune indications and developing a next-generation platform for tissue-targeted complement inhibition.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases

Other Alopecia Areata Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
Stem Cell Educator Therapy	Throne Biotechnologies	Phase 2	Active
RO-7239361 (BMS-986166)	Rohto Pharmaceutical	Phase 2	Active
Rezpegaldesleukin	Nektar Therapeutics	Phase 2b	Active, not recruiting
Exploratory Asset	Veradermics	Discovery	Research
ATI-2138	Aclaris Therapeutics	Phase 2a	Completed